Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

Most effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline says Certain GLP-1 drugs are best for specific complications The non-binding guideline ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

Of the title character in “Lost Evangeline,” it is said she “lived a great life of the imagination.” You could say the same about Evangeline’s creator, Kate DiCamillo. The beloved, Minneapolis-based ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

Lilly expects to open 615 high-wage roles in Texas in connection with its new facility, plus around 4,000 construction roles. The next stop on Eli Lilly’s multibillion-dollar manufacturing blitz is ...

EVANGELINE PARISH, La (KLFY) — Evangeline Parish is set to open a new multimillion-dollar jail facility which will significantly expand its inmate capacity. The new jail, currently under construction, ...

US appeals court in Chicago upholds jury verdict, damages Jury found Lilly didn't rebate Medicaid for higher prices Lilly disagrees with decision, plans appeal Sept 11 (Reuters) - A federal appeals ...

As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders. The Big Pharma had been running three midstage studies of the ...

Eli Lilly LLY0.96%increase; green up pointing triangle said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory ...

is an experienced journalist with a diverse background in reporting, anchoring, and digital media. CORPUS CHRISTI, Texas — A proposed brackish groundwater deal that once appeared affordable is now ...

Eli Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion Therapeutics while adding a candidate from its recent SiteOne Therapeutics buyout to its early-phase ...